Stocks in Hong Kong are on the move, with Luopei Biotechnology-B (02157.HK) rising over 7% in the afternoon. The CDH17-targeted ADC has been granted clinical approval, and the drug had already obtained overseas authorization earlier this year.

According to the AI Finance App, Lepu Medical-B (02157.HK) rose more than 7% in the afternoon, with a current increase of 5.45% as of the time of writing, trading at 5.61 Hong Kong dollars, with a trading volume of 94.05 million Hong Kong dollars.